Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Mount Gilead traveled to Cardington for a rivalry girls basketball game in the Knox Morrow Athletic Conference on Friday ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.37 which represents a slight increase of $0.36 or 0.39% from the prior close of $92.01. The stock opened at $92.59 and ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 21,980,000 ...

Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%.

Gilead Sciences Inc. closed $7.02 below its 52-week high ($98.90), which the company achieved on November 11th.